|

Carboplatin Injection Clinical Trials

12 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Carboplatin, NSC 241240

Pipeline

Phase 2: 5Phase 3: 4Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • BeBetter Med Inc3
  • Shanghai Hengrui Pharmaceutical Co., Ltd.2
  • Allist Pharmaceuticals, Inc.2
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1

Indications

  • Cancer12
  • Lung Cancer5
  • Advanced Cervical Cancer1
  • Advanced Solid Tumour1
  • Recurrent or Metastatic1

Other12 trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Phase 3
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2/3
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Phase 2
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Phase 1/2
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Phase 1/2
SKB500 Combinations in Patients With Small Cell Lung Cancer
Phase 2
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.